Chelation therapy for neurodegenerative diseases
- 28 January 2009
- journal article
- review article
- Published by Wiley in Medicinal Research Reviews
- Vol. 29 (4), 547-570
- https://doi.org/10.1002/med.20148
Abstract
Mounting evidence suggests a central role for transition biometals in the etiopathogenesis of neurodegenerative diseases (ND). Indeed, while studying the molecular basis for this heterogeneous group of diseases, it has become increasingly evident that biometals and nonphysiological Al are often involved in pathology onset and progression, either by affecting the conformation of specific proteins or by exacerbating local oxidative stress. The apparently critical role played by metal dishomeostasis in ND makes chelation therapy an attractive pharmacological option. However, classical metal chelation approaches, relying on potent metal ligands, turned out to be successful only in those rare cases where exceptional brain metal accumulation occurs due to specific defects in metal metabolism. In contrast, metal‐targeted approaches using ligand of intermediate strength seem to be more appropriate in fighting the major ND, although their benefits are still questioned. We report here a survey of recent evidences supporting the use of a variety of metal ligands, and even functionalized nanoparticles, for the treatment of the most common ND. The beneficial neuropharmacological actions of metal‐targeted agents most likely arise from local metal redistribution rather than from massive metal removal. The perspectives for the development of new effective agents against ND are critically discussed. © 2009 Wiley Periodicals, Inc. Med Res RevKeywords
This publication has 136 references indexed in Scilit:
- The crucial role of metal ions in neurodegeneration: the basis for a promising therapeutic strategyBritish Journal of Pharmacology, 2005
- β-Lactam antibiotics are multipotent agents to combat neurological diseasesBiochemical and Biophysical Research Communications, 2005
- Clioquinol, a Drug for Alzheimer's Disease Specifically Interfering with Brain Metal Metabolism: Structural Characterization of Its Zinc(II) and Copper(II) ComplexesInorganic Chemistry, 2004
- Role of the prion protein in copper turnover in astrocytesNeurobiology of Disease, 2004
- Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson?s disease and other neurodegenerative diseasesJournal of Neural Transmission, 2004
- Protein aggregation and aggregate toxicity: new insights into protein folding, misfolding diseases and biological evolutionJournal of Molecular Medicine, 2003
- Electron microscopic analysis of nanoparticles delivering thioflavin-T after intrahippocampal injection in mouse: implications for targeting β-amyloid in Alzheimer's diseaseNeuroscience Letters, 2003
- Amyloidosis and Alzheimer’s diseaseAdvanced Drug Delivery Reviews, 2002
- Filamentous α-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodiesNeuroscience Letters, 1998
- Neurochemical enzyme changes in Alzheimer's and Pick's diseaseArchives of Gerontology and Geriatrics, 1984